-
Mashup Score: 21Why is the NHS in its worst ever crisis? - 3 year(s) ago
The NHS is facing what health leaders say is the worst crisis in its history. Hospital trusts and ambulance services across England are declaring critical incidents, and waiting times for admission to accident and emergency departments have reached unprecedented levels.
Source: Financial TimesCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 0Optimizing the value of lenalidomide maintenance by genetic profiling - an analysis of 556 Myeloma XI trial patients - 3 year(s) ago
Key Points. Myeloma patients with isolated del(1p), del(17p), t(4;14) derive exceptional benefit from lenalidomide maintenance post transplantationPatients with
Source: American Society of HematologyCategories: Latest Headlines, Oncologists2Tweet-
We had an early Christmas with our team's latest work out in @BloodJournal. We investigated the benefit patients derive from Lenalidomide Maintenance in context of tumour genetics. https://t.co/DiNm4l8PJB
-
-
Mashup Score: 2
Oral and Poster Abstracts Oral 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Prognostic Markers in Multiple Myeloma Research, clinical trials, adult, Translational Research, Clinical Research, Plasma Cell Disorders, Combination therapy, genomics, Diseases, Therapies, Lymphoid Malignancies, Biological Processes, Technology and Procedures, Study…
Source: ash.confex.comCategories: Latest Headlines, Oncologists2Tweet-
A frosty start but very much looking forward to meeting old friends & hopefully making new ones at #ASH22 . Grateful to present our results on better diagnosis and more personalised approaches for patients with #highriskMM #MMsm https://t.co/gljsjlgkBk https://t.co/7WQ5KC0aI2 https://t.co/Z3VajSJEqG
-
-
Mashup Score: 1064th ASH Annual Meeting and Exposition - 3 year(s) ago
64th ASH Annual Meeting and Exposition
Categories: Hem/Oncs, Latest HeadlinesTweet-
RT @ASH_hematology: The #ASH22 virtual platform is officially OPEN! Start exploring now 🧑💻: https://t.co/UKP5C16Fcr https://t.co/59GoiHbs78
-
RT @ASH_hematology: The #ASH22 virtual platform is officially OPEN! Start exploring now 🧑💻: https://t.co/UKP5C16Fcr https://t.co/59GoiHbs78
-
-
Mashup Score: 1
Oral and Poster Abstracts Oral 653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Risk-adapted Treatment Strategies in Myeloma and Related Conditions Research, clinical trials, adult, Clinical Research, Plasma Cell Disorders, Combination therapy, genomics, Diseases, Therapies, Lymphoid Malignancies, Biological Processes, Technology and Procedures, Study…
Source: ash.confex.comCategories: Latest Headlines, Oncologists2Tweet-
RT @szusmani: -High risk NDMM enrichment trials to watch for #ASH22: https://t.co/LkBJfkhQFg (MRC UK Dara-RVd)https://t.co/KoBx8sHJou (GMMG…
-
-
Mashup Score: 1
Oral and Poster Abstracts 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III adult, Research, epidemiology, Plasma Cell Disorders, Clinical Research, Diseases, Lymphoid Malignancies, Human, Study Population Ingigerdur S Sverrisdottir, MD1,2*, Sigrún Thorsteinsdóttir, MD, PhD2,3, Sæmundur Rögnvaldsson, MD4*, Thor…
Source: ash.confex.comCategories: Latest Headlines, Oncologists2Tweet-
RT @sykristinsson: https://t.co/ydzq9PihCJ Autoimmunity is well established risk factor for MGUS an MM. Think again! Presenter: @ingigerdu…
-
-
Mashup Score: 3Paper: Hypercalcemia in Individuals with Monoclonal Gammopathy of Undetermined Significance: Results from the Istopmm Study - 3 year(s) ago
Oral and Poster Abstracts 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III Research, adult, Clinical Practice (Health Services and Quality), elderly, Plasma Cell Disorders, Diseases, Lymphoid Malignancies, Study Population, Human Ástrún Helga Jónsdóttir1*, Sæmundur Rögnvaldsson, MD1,2*, Helga Ágústa…
Source: ash.confex.comCategories: Latest Headlines, Oncologists2Tweet-
RT @sykristinsson: https://t.co/8jfMTQluaf The “C“ in CRAB does not walk alone! Checking s-calcium in 2546 individuals with MGUS: 7.5% h…
-
-
Mashup Score: 2
Oral and Poster Abstracts 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III Research, epidemiology, Clinical Research, Plasma Cell Disorders, Diseases, Lymphoid Malignancies Thorir Einarsson Long, MD, PhD1,2,3*, Elias Eythorsson, MD, PhD4*, Sæmundur Rögnvaldsson, MD5,6*, Olafur Indridason, MD, MHS7*, Runolfur Palsson,…
Source: ash.confex.comCategories: Latest Headlines, Oncologists2Tweet-
RT @sykristinsson: https://t.co/kNKC6qvvu0 Looking for M-proteins in everyone with kidney disease? Presenter: @thorirlong Prospective po…
-
-
Mashup Score: 5Whole-body MRI: review of MET-RADS, MY-RADS & ONCO-RADS. Dr Messiou & Profs Padhani, Petralia & Koh - 3 year(s) ago
Presented by Dr. Christina Messiou, Prof. Anwar Padhani, Prof. Giuseppe Petralia and Dow-Mu Koh (Chair). This webinar took place on Wednesday 6 July 2022.The…
Source: YouTubeCategories: Latest Headlines, Oncologists2Tweet-
RT @ProfPadhani: All the WB-MRI #RADS in one place FROM #ICIS International Cancer Imaging society 2022... https://t.co/YBnmEiAevx
-
-
Mashup Score: 3
The FDA has approved the first at-home therapy for skin repigmentation in vitiligo, a condition that affects millions of people.
Source: STATCategories: Latest Headlines, Oncologists2Tweet-
RT @matthewherper: FDA approves first at-home therapy for skin repigmentation in vitiligo https://t.co/QBuFJ42fxC
-
RT @adamjkucharski: Yesterday's trends can become tomorrow's problems... https://t.co/Xw5DrIilYZ https://t.co/xCC98hqJzM